Literature DB >> 23152343

The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil.

Doracy Silva Diniz1, Alexandre Sylvio Vieira Costa, Patrícia Maria Fonseca Escalda.   

Abstract

INTRODUCTION: Governador Valadares is an endemic area of American tegumentary leishmaniasis (ATL). The detection rate was 15.36 per 100,000 habitants from 2001 to 2006 (Miranda, 2008). This study aimed to analyze the effects of age on the frequency of adverse reactions caused by antimony in the treatment of ATL in the City of Governador Valadares, State of Minas Gerais, Brazil, during 2009.
METHODS: Data were collected from the forms of the Information System for Notifiable Diseases, and from charts, questionnaires, and home visits to patients.
RESULTS: The study included 40 patients, 26 (65%) of whom were males. Individuals over the age of 50 had a 66% higher rate of adverse effects than subjects who were 50 years old or less (CI 95%, 1.14-2.41). The average age of individuals who reported some type of adverse effect was 44.11 years (SD = 20.14), while the average age of the group that did not report any adverse effect was of 25.46 years (SD = 18.37; p < 0.01). Clinical healing was 67.5%, and 10% of patients discontinued the treatment.
CONCLUSIONS: In the treatment of ATL, the age of patients should be considered, because most adverse reactions occur in individuals over 50 years of age. For this reason, the drug should be used with restriction in these cases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152343     DOI: 10.1590/s0037-86822012000500011

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  7 in total

1.  Age modifies the immunologic response and clinical presentation of American tegumentary leishmaniasis.

Authors:  Augusto M Carvalho; Camila F Amorim; Juliana L S Barbosa; Alexsandro S Lago; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

2.  The Elderly Respond to Antimony Therapy for Cutaneous Leishmaniasis Similarly to Young Patients but Have Severe Adverse Reactions.

Authors:  Alexsandro Souza do Lago; Maurício Nascimento; Augusto M Carvalho; Neuza Lago; Juliana Silva; José Roberto Queiroz; Lucas P Carvalho; Albert Schriefer; Mary Wilson; Paulo Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2018-03-22       Impact factor: 2.345

3.  Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.

Authors:  Mauricio Naoto Saheki; Marcelo Rosandiski Lyra; Sandro Javier Bedoya-Pacheco; Liliane de Fátima Antônio; Maria Inês Fernandes Pimentel; Mariza de Matos Salgueiro; Érica de Camargo Ferreira E Vasconcellos; Sonia Regina Lambert Passos; Ginelza Peres Lima Dos Santos; Madelon Novato Ribeiro; Aline Fagundes; Maria de Fátima Madeira; Eliame Mouta-Confort; Mauro Célio de Almeida Marzochi; Cláudia Maria Valete-Rosalino; Armando de Oliveira Schubach
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

4.  Treatment of cutaneous leishmaniasis with thermotherapy in Brazil: an efficacy and safety study.

Authors:  Sheila Viana Castelo Branco Gonçalves; Carlos Henrique Nery Costa
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

5.  An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.

Authors:  Carla Oliveira-Ribeiro; Maria Inês Fernandes Pimentel; Liliane de Fátima Antonio Oliveira; Érica de Camargo Ferreira E Vasconcellos; Fatima Conceição-Silva; Armando de Oliveira Schubach; Aline Fagundes; Cintia Xavier de Mello; Eliame Mouta-Confort; Luciana de Freitas Campos Miranda; Claudia Maria Valete-Rosalino; Ana Cristina da Costa Martins; Raquel de Vasconcellos Carvalhaes de Oliveira; Leonardo Pereira Quintella; Marcelo Rosandiski Lyra
Journal:  PLoS Negl Trop Dis       Date:  2021-09-23

6.  Multiparametric analysis of host and parasite elements in new world tegumentary leishmaniasis.

Authors:  Bruna Caroline de Carvalho; Tamires Vital; Jaqueline Osiro; Ciro Martins Gomes; Elza Noronha; Bruno Dallago; Ana de Cássia Rosa; Juliana Lott Carvalho; Luciana Hagström; Mariana Hecht; Nadjar Nitz
Journal:  Front Cell Infect Microbiol       Date:  2022-08-09       Impact factor: 6.073

7.  Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area.

Authors:  Daniel Holanda Barroso; Renata Trindade Gonçalves; Joadyson Silva Barbosa; Jorgeth de Oliveira Carneiro da Motta; Gustavo Subtil Magalhães Freire; Ciro Martins Gomes; Raimunda Nonata Ribeiro Sampaio
Journal:  Front Cell Infect Microbiol       Date:  2022-09-23       Impact factor: 6.073

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.